Page last updated: 2024-09-04

naproxen and paroxetine

naproxen has been researched along with paroxetine in 11 studies

Compound Research Comparison

Studies
(naproxen)
Trials
(naproxen)
Recent Studies (post-2010)
(naproxen)
Studies
(paroxetine)
Trials
(paroxetine)
Recent Studies (post-2010) (paroxetine)
4,5511,0571,4294,2571,0311,031

Protein Interaction Comparison

ProteinTaxonomynaproxen (IC50)paroxetine (IC50)
Voltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)3.9
MyeloperoxidaseHomo sapiens (human)0.02
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)0.086
Muscarinic acetylcholine receptor M2Homo sapiens (human)0.532
Muscarinic acetylcholine receptor M4Homo sapiens (human)0.244
Muscarinic acetylcholine receptor M5Homo sapiens (human)0.123
Quinolone resistance protein NorAStaphylococcus aureus7
Cytochrome P450 2D6Homo sapiens (human)0.5003
Muscarinic acetylcholine receptor M1Homo sapiens (human)0.145
Muscarinic acetylcholine receptor M3Homo sapiens (human)0.179
Beta-adrenergic receptor kinase 1Bos taurus (cattle)1.08
Sodium-dependent noradrenaline transporter Homo sapiens (human)0.093
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)0.623
Beta-adrenergic receptor kinase 1Homo sapiens (human)1.24
Substance-P receptorHomo sapiens (human)0.9
Sodium-dependent serotonin transporterHomo sapiens (human)0.0007
Sodium-dependent serotonin transporterRattus norvegicus (Norway rat)0.0003
P2X purinoceptor 4Rattus norvegicus (Norway rat)2.45
Voltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)3.9
Sodium-dependent dopamine transporter Homo sapiens (human)0.672
Voltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)3.9
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)3.9
P2X purinoceptor 4Homo sapiens (human)2.8067
Sigma non-opioid intracellular receptor 1Homo sapiens (human)5.366
TransporterRattus norvegicus (Norway rat)0.535

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (18.18)29.6817
2010's9 (81.82)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Topliss, JG; Yoshida, F1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
García-Mera, X; González-Díaz, H; Prado-Prado, FJ1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ1
Ekins, S; Williams, AJ; Xu, JJ1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Bellman, K; Knegtel, RM; Settimo, L1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Jones, LH; Nadanaciva, S; Rana, P; Will, Y1

Reviews

1 review(s) available for naproxen and paroxetine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

10 other study(ies) available for naproxen and paroxetine

ArticleYear
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
    Bioorganic & medicinal chemistry, 2010, Mar-15, Volume: 18, Issue:6

    Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics

2010
Developing structure-activity relationships for the prediction of hepatotoxicity.
    Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
    Pharmaceutical research, 2014, Volume: 31, Issue:4

    Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation

2014
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
    Bioorganic & medicinal chemistry letters, 2016, 08-15, Volume: 26, Issue:16

    Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone

2016